<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03935958</url>
  </required_header>
  <id_info>
    <org_study_id>2019-0321</org_study_id>
    <nct_id>NCT03935958</nct_id>
  </id_info>
  <brief_title>Curcumin in Kidney Transplant Recipients</brief_title>
  <official_title>A Pilot 12 Month, Randomized, Controlled Trial of Curcumin in Kidney Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Verdure Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this study is to investigate if curcumin is beneficial for kidney&#xD;
      transplant recipients, a population with extensive baseline vascular dysfunction and&#xD;
      cognitive impairment who have few treatment options. The possible mechanisms by which&#xD;
      curcumin improves vascular function will be evaluated as well as whether curcumin improves&#xD;
      cognitive function in these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Kidney transplant recipients are at increased risk of death from cardiovascular disease&#xD;
      (CVD). Inflammation, oxidative stress and vascular dysfunction (impaired endothelial function&#xD;
      and increased large elastic artery stiffness), are highly prevalent in kidney transplant&#xD;
      recipients and contribute to the high incidence of CVD in this patient population. The most&#xD;
      common cause of kidney transplant failure is interstitial fibrosis and tubular atrophy&#xD;
      (IFTA). The incidence of IFTA is as high as 50% of kidney transplants at 1 year after&#xD;
      transplantation. The pathophysiology of IFTA is not well understood. Possible mechanisms&#xD;
      include chronic rejection or injury, inflammation, and drug toxicity. Kidney transplant&#xD;
      recipients suffer from high rates of cognitive decline for which the investigators lack&#xD;
      effective therapies. Thus, therapeutic interventions targeting inflammation, oxidative&#xD;
      stress, vascular dysfunction, and cognitive impairment are a priority.&#xD;
&#xD;
      Curcumin may have positive effects in terms of cardiovascular and nephroprotection because of&#xD;
      its antibacterial, antiviral, anti-inflammatory and anti-oxidative effects. The aim of this&#xD;
      study is to elucidate the role of curcumin as a nutritional strategy to reduce cardiovascular&#xD;
      risk factors as well as inflammation and oxidative stress in kidney transplant recipients.&#xD;
      The study aims to examine if curcumin will improve endothelial function by reducing markers&#xD;
      of inflammation and oxidative stress. In addition, the study will evaluate the potential&#xD;
      benefit of curcumin on cognitive function in kidney transplant recipients.&#xD;
&#xD;
      Curcumin is a natural polyphenol with anti-inflammatory and antioxidant characteristics.&#xD;
      Preliminary data indicate that curcumin administration improves endothelial dysfunction by&#xD;
      reducing oxidative stress and inflammation and may improve cognitive function.&#xD;
&#xD;
      The primary goal of this study is to investigate if curcumin is beneficial for kidney&#xD;
      transplant recipients, a population with extensive baseline vascular dysfunction and&#xD;
      cognitive impairment who have few treatment options. The possible mechanisms by which&#xD;
      curcumin improves vascular function will be evaluated as well as whether curcumin improves&#xD;
      cognitive function in these patients.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
        1. Evaluate the effects of curcumin on kidney transplant graft function&#xD;
&#xD;
        2. Evaluate the effects of curcumin supplementation on cognitive function.&#xD;
&#xD;
        3. Evaluate the effects of curcumin on diabetes and cardiovascular outcomes&#xD;
&#xD;
        4. Evaluate the effects of curcumin on systemic and endothelial cell markers of&#xD;
           inflammation and oxidative stress.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      Patients will be randomized 1:1 to receive either curcumin or placebo starting at the time of&#xD;
      transplant or up to 2 weeks prior to transplant. Patients will be followed per standard of&#xD;
      care for kidney transplant recipients. Additional blood (30mL) and urine samples will be&#xD;
      drawn prior to transplant and at 3, 6 and 12 months post-transplant to be used for future&#xD;
      analysis. There will be a total of 4 visits for this study. Additionally, two questionnaires&#xD;
      will be distributed at each visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">May 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>20 participants in supplement (receiving curcumin) group 20 participants in control (receiving placebo) group&#xD;
randomization 1:1</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>participants will not know if they are receiving curcumin or placebo</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Graft Outcomes</measure>
    <time_frame>12 months</time_frame>
    <description>Change in GFR at 3, 6 and 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diabetes Outcomes</measure>
    <time_frame>12 months</time_frame>
    <description>Change in A1C at 0, 3 6, and 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular Outcomes</measure>
    <time_frame>12 months</time_frame>
    <description>Change in total cholesterol at 0, 3, 6 and 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>12 months</time_frame>
    <description>Change in Neuro-QOL Item Bank v2.0 at 0, 3, 6, and 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Graft Outcomes</measure>
    <time_frame>12 months</time_frame>
    <description>Difference in biopsy scores at 3, 6 and 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>12 months</time_frame>
    <description>Change in SF-36 at 0, 3, 6, and 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular Outcomes</measure>
    <time_frame>12 months</time_frame>
    <description>Change in total cholesterol and LDL-C at 0, 3, 6 and 12 months</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Disorder Related to Renal Transplantation</condition>
  <arm_group>
    <arm_group_label>Curcumin Arm (Arm 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 subjects will be randomized (1:1) to this arm and receive curcumin for a year. In addition, subjects will have four study visits at Day 0, and 3, 6 and 12 months post-transplant. These study visits also include blood and urine samples and questionnaires.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm (Arm 2)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 subjects will be randomized (1:1) to this arm and receive placebo for a year. In addition, subjects will have four study visits at Day 0, and 3, 6 and 12 months post-transplant. These study visits also include blood and urine samples and questionnaires.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Curcumin</intervention_name>
    <description>Patients will receive curcumin (Longvida) 2000 mg, once a day, for 12 months</description>
    <arm_group_label>Curcumin Arm (Arm 1)</arm_group_label>
    <other_name>Longvida</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will receive placebo capsule identical in appearance and taste to the supplement, for 12 months</description>
    <arm_group_label>Placebo Arm (Arm 2)</arm_group_label>
    <other_name>Longvida</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The subject is a recipient of a living donor or deceased donor kidney only transplant&#xD;
&#xD;
          2. The subject is &gt; 18 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The subject has had a multi-organ transplant&#xD;
&#xD;
          2. Subjects that were taking curcumin pre-transplant&#xD;
&#xD;
          3. Subjects that have a BMI &gt; 35 kg/m2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierpaolo Di Cocco, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ali BH, Al-Salam S, Al Suleimani Y, Al Kalbani J, Al Bahlani S, Ashique M, Manoj P, Al Dhahli B, Al Abri N, Naser HT, Yasin J, Nemmar A, Al Za'abi M, Hartmann C, Schupp N. Curcumin Ameliorates Kidney Function and Oxidative Stress in Experimental Chronic Kidney Disease. Basic Clin Pharmacol Toxicol. 2018 Jan;122(1):65-73. doi: 10.1111/bcpt.12817. Epub 2017 Jul 10.</citation>
    <PMID>28561324</PMID>
  </reference>
  <reference>
    <citation>Sun X, Liu Y, Li C, Wang X, Zhu R, Liu C, Liu H, Wang L, Ma R, Fu M, Zhang D, Li Y. Recent Advances of Curcumin in the Prevention and Treatment of Renal Fibrosis. Biomed Res Int. 2017;2017:2418671. doi: 10.1155/2017/2418671. Epub 2017 May 4. Review.</citation>
    <PMID>28546962</PMID>
  </reference>
  <reference>
    <citation>Shoskes D, Lapierre C, Cruz-Correa M, Muruve N, Rosario R, Fromkin B, Braun M, Copley J. Beneficial effects of the bioflavonoids curcumin and quercetin on early function in cadaveric renal transplantation: a randomized placebo controlled trial. Transplantation. 2005 Dec 15;80(11):1556-9. Erratum in: Transplantation. 2006 Sep 15;82(5):715. Cruz-Corerra, Marcia [corrected to Cruz-Correa, Marcia].</citation>
    <PMID>16371925</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 23, 2019</study_first_submitted>
  <study_first_submitted_qc>April 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2019</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Pierpaolo Di Cocco</investigator_full_name>
    <investigator_title>Warren H. Cole Chair in Surgery, Professor and Head of Surgery, Medical Director, Abdominal Organ Transplant Program</investigator_title>
  </responsible_party>
  <keyword>kidney transplantation</keyword>
  <keyword>inflammation</keyword>
  <keyword>vascular dysfunction</keyword>
  <keyword>cognitive impairment</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>graft function</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

